🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Browsing Tag

Niclas Neglen

1 post
Read More

Adyen (AMS: ADYEN) processes €451bn, drops 13%. Why abandon its margin goal?

Adyen delivered 23% net revenue growth and processed €451.1 billion in payments, yet its shares plunged after management reduced profitability guidance and abandoned its medium-term EBITDA margin target. The decision raises a critical question about whether expanding into billing, loyalty and AI-enabled commerce will justify sacrificing near-term margins.